Fluvastatin
- Atc Codes:C10AA04
- CAS Codes:93957-55-2#93957-54-1
- PHARMGKB ID:93957-55-2#93957-54-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Fluvalescobene, Fluvastatin, Lescol, Nuvastin; Belgium: Lescol; Bulgaria: Lescol, Luvinsta; Cyprus: Lescol; Czech Republic: Fluvakarav, Fluvaratio, Fluvastatin, Fuvatalip, Lescol, Vuyator; Denmark: Fluvastatin, Lescol; Estonia: Fluvastatin, Lescol; Finland: Fluvastatin, Lescol; France: Fluvastatine, Fractal, Lescol; Germany: Cranoc, Edestatin, Evadanin XL, Fedivan, Flumisden, Fluvaham, Fluvastatin, Fluvatamed, Fluvatifi, Lescol, Locol, Lumecine, Mefiden, Stefluvin, Vesfim, Vespaten; Greece: Fluvastatin, Lescol; Hungary: Fluvastatin, Lescol, Luvinsta, Stipatin; Ireland: Fluvastatin, Fluvat, Lescol, Lochol, Luvinsta, Statease; Italy: Fluvastatina, Lescol, Lipaxan, Primesin; Latvia: Fluvastatin, Lescol; Lithuania: Fluvastatin, Lescol; Malta: Lescol, Luvinsta; Netherlands: Fluvastatine, Lescol; Poland: Fluvagen, FluvaHexal, FluvaLek, Fluvastad, Lescol; Portugal: Canef, Cardiol XL, Fluvastatina, Lescol; Romania: Lescol, Luvinsta; Slovakia: Fluvabene, Fluvastatin, Lescol, Vuyator; Slovenia: Fluvastatin, Lescol, Vuyator; Spain: Digaril, Fluvastatina, Lescol, Liposit, Lymetel, Vaditon; Sweden: Flavicen, Fluvasin, Fluvastatin, Lescol; UK: Fluvastatin, Lescol, Luvinsta.
North America
Canada: Lescol; USA: Lescol.
Latin America
Argentina: Lescol; Brazil: Lescol; Mexico: Lescol, Vastaflux.
Asia
Japan: Lochol.
Drug combinations
Chemistry
Fluvastatin Sodium: C~24~H~25~FNNaO~4~. Mw: 433.45. (1) 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, monosodium salt, [R*,S*-(E)]-(±)-; (2) Sodium (±)-(3R*,5S*,6E)-7-[3-(p-fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxy-6-heptenoate. CAS-93957-55-2; CAS-93957-54-1 (fluvastatin)(1989).
Pharmacologic Category
Antilipemic Agents, HMG-CoA Reductase Inhibitors. (ATC-Code: C10AA04).
Mechanism of action
Acts by competitively inhibiting 3-hydroxyl-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGCR), the enzyme that catalyzes reduction of HMG-CoA to mevalonate. HDL is increased while total, LDL and VLDL cholesterols, apolipoprotein B, and plasma triglycerides are decreased.
Therapeutic use
Used as a component of multiple risk factor intervention in patients at risk for atherosclerosis vascular disease due to hypercholesterolemia.
Pregnancy and lactiation implications
Cholesterol biosynthesis may be important in fetal development. Contraindicated in pregnancy, or breast-feeding.
Unlabeled use
Contraindications
Hypersensitivity to fluvastatin or any component of the formulation. Active liver disease. Unexplained persistent elevations of serum transaminases. Pregnancy. Breast-feeding.
Warnings and precautions
Patients receiving HMG-CoA reductase inhibitors developed rhabdomyolysis with acute renal failure and/or myopathy. Use caution in renal impairment, inadequately-treated hypothyroidism, and patients taking other drugs associated with myopathy (e.g. colchicine). Use caution in patients with conditions or on medications that reduce steroidogenesis. Use with caution in patients who consume large amounts of ethanol or have history of liver disease. Use with caution in elderly patients (predisposed to myopathy). Treatment in patients <18 years of age not recommended. Secondary causes of hyperlipidemia should be ruled out prior to therapy.